Stingx

Description

The product is identified by the SPL code 34089-3. No additional specific description details are provided in the available text.

Uses and Indications

This drug is indicated for the temporary relief of pain associated with insect bites and stings.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The medication should be applied to the affected area no more than 3 to 4 times daily. This dosing regimen is applicable for both adults and children aged 2 years and older. Care should be taken to ensure that the application is limited to the specified frequency to avoid potential overuse.

Contraindications

Use is contraindicated in the following situations:

• Application in or near the eyes is prohibited due to the risk of irritation or damage to ocular tissues.

• Application over large areas of the body is not recommended, as it may lead to systemic absorption and potential adverse effects.

• Use on raw or blistered areas is contraindicated to prevent exacerbation of the condition and to avoid further irritation or infection.

Warnings and Precautions

For external use only. This product is contraindicated for application in or near the eyes, over large areas of the body, or on raw or blistered areas.

Healthcare professionals should advise patients to discontinue use and seek medical attention if conditions worsen or persist for more than 7 days, or if symptoms clear up and then recur within a few days.

In the event of accidental ingestion, it is imperative to obtain emergency medical assistance or contact a Poison Control center immediately.

Side Effects

Patients should be aware that the product is intended for external use only. It is contraindicated for use in or near the eyes, over large areas of the body, or on raw or blistered areas.

In clinical practice, patients are advised to discontinue use and consult a healthcare professional if their condition worsens, persists for more than 7 days, or if symptoms clear up and then recur within a few days. These precautions are essential to ensure the safe and effective use of the product.

Drug Interactions

No drug interactions or drug and laboratory test interactions have been identified in the available data. Therefore, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Stingx (benzocaine). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 2 years and older may apply the medication to the affected area no more than 3 to 4 times daily. It is important to keep the product out of reach of children. In the event of accidental ingestion, medical assistance should be sought immediately, or the Poison Control center should be contacted.

Geriatric Use

There is no specific information regarding the use of STINGX (benzocaine swab) in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when administering this product to elderly patients, as the absence of data necessitates careful consideration of individual patient factors and potential risks. Monitoring for adverse effects is advisable in this population, given the lack of established guidelines for geriatric use.

Pregnancy

There is no information available regarding the use of STINGX (benzocaine swab) during pregnancy, including safety concerns, dosage modifications, or any special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients and weigh the potential risks and benefits. Women of childbearing potential should be advised to discuss their pregnancy status and any plans for pregnancy with their healthcare provider before using this product.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or its effects on lactation. Consequently, healthcare professionals should exercise caution when prescribing this medication to lactating mothers, as the potential risks to breastfed infants are not well characterized. It is advisable to consider the benefits of breastfeeding alongside the potential risks associated with the medication.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this medication. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the prescribing information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include monitoring vital signs, providing symptomatic treatment, and ensuring the patient's safety.

If available, consultation with a poison control center or a medical toxicologist is recommended to guide further management and treatment options.

Documentation of the incident, including the amount and timing of the substance taken, is crucial for effective management and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients that in the event of accidental ingestion, it is crucial to seek medical assistance immediately or contact the Poison Control Center. This prompt action is essential to ensure the safety and well-being of the patient.

Storage and Handling

The product is available in various package configurations, identified by their respective NDC numbers. Specific storage and handling instructions are not provided; therefore, standard practices for pharmaceutical products should be followed. It is recommended to store the product in a controlled environment, ensuring that it is kept at appropriate temperatures to maintain its integrity. Containers should be kept sealed and protected from light and moisture to prevent degradation. Special handling requirements are not specified, but general precautions should be taken to ensure the product's quality and safety during storage and transport.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Stingx, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)